Faze Medicines

Faze Medicines was a biotechnology company based in Cambridge, Massachusetts, founded in 2020.

The company focused on developing therapeutics based on biomolecular condensates, which are clusters of proteins and nucleic acids that play a role in cellular functions. Faze was established by prominent scientists in the field and received significant funding from Third Rock Ventures and other investors. The company aimed to create treatments for neurodegenerative diseases and other conditions with high unmet needs, including Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), and various cancers. Faze Medicines operated in the B2B space within the Life Sciences market, targeting partnerships with the pharmaceutical industry and investors. Faze Medicines ceased operations in November 2022, less than two years after its launch, despite initial funding of $81 million.